Lipoprotein(a) as a Determinant of Coronary Heart Disease in Young Women: A Stronger Risk Factor Than Diabetes?

Circulation ◽  
1998 ◽  
Vol 97 (3) ◽  
pp. 293-295 ◽  
Author(s):  
Enas A. Enas
Keyword(s):  
Coronary Heart Disease ◽  
Risk Factor ◽  
Heart Disease ◽  
Young Women ◽  
Lipoprotein A

Lipoprotein(a) as a risk factor for coronary heart disease in heterozygous patients for familial hypercholesterolemia

1995 ◽  
Vol 115 ◽  
pp. S91
Author(s):  
C. Mussoni ◽  
L. Finazzo ◽  
A. Dormi ◽  
Z. Sangiorgi ◽  
S. Rimondi ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Risk Factor ◽  
Heart Disease ◽  
Familial Hypercholesterolemia ◽  
Lipoprotein A

scholarly journals Effect of ageing on plasma lipoprotein(a) levels

2002 ◽  
Vol 39 (3) ◽  
pp. 237-240 ◽  
Author(s):  
Harukuni Akita ◽  
Miyao Matsubara ◽  
Hitoshi Shibuya ◽  
Hirotoshi Fuda ◽  
Hitoshi Chiba
Keyword(s):  
Molecular Weight ◽  
Coronary Heart Disease ◽  
Risk Factor ◽  
Heart Disease ◽  
The Elderly ◽  
Low Molecular Weight ◽  
Lipoprotein A ◽  
Significant Difference ◽  
The Mean ◽  
Japanese Subjects

Background Lipoprotein(a) [Lp(a)] is a risk factor for atherosclerosis and increases with age. The purpose of this study was to determine the effect of ageing on Lp(a) for three different apo(a) phenotypes. Methods We measured plasma Lp(a) concentrations in 551 unrelated Japanese subjects (20-88 years of age). We performed statistical analyses separately for three apo(a) phenotypes: the low-molecular-weight (LMW) phenotype with the F, B or S1 isoform, the intermediate-molecular-weight (IMW) phenotype with the S2 isoform and the high-molecular-weight (HMW) phenotype with the S3 or S4 isoform. Results For each phenotype, the mean plasma Lp(a) concentration and the frequency of Lp(a) concentrations ≥ 250 mg/L increased with age. Further, a statistically significant difference was always found between the younger subjects (20-39 years of age) and the elderly (over 60 years). The frequency of coronary heart disease increased with age, particularly for the LMW and IMW phenotypes. Conclusions We conclude that ageing elevates plasma Lp(a) concentrations, which may have a role in the prevalence of coronary heart disease in the elderly, especially those with the LMW or IMW phenotypes.

Lipoprotein(a) in coronary heart disease. Is it a risk factor after all?

JAMA ◽  
1994 ◽  
Vol 271 (13) ◽  
pp. 1025-1026 ◽  
Author(s):  
V. Gurewich
Keyword(s):  
Coronary Heart Disease ◽  
Risk Factor ◽  
Heart Disease ◽  
Lipoprotein A

P5528Extremely elevated lipoprotein (a) as an independent risk factor for coronary heart disease in large patient cohort

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
M R Poudel ◽  
S Kirana ◽  
K P Mellwig ◽  
D Horstkotte ◽  
C Knabbe ◽  
...  
Keyword(s):  
Risk Factors ◽  
Coronary Heart Disease ◽  
Risk Factor ◽  
Heart Disease ◽  
Independent Risk Factor ◽  
The United States ◽  
Lipoprotein A ◽  
Vessel Disease ◽  
Large Patient ◽  
Increased Risk

Abstract Background Elevated lipoprotein (a) [LP (a)] levels are an independent risk factor for coronary heart disease (CHD) and associated with myocardial infarction (MI). CHD took a devastating toll in Europe and in the United States in the 20th century, killing more people than any other disease. It remains the leading cause of death in most countries worldwide. CHD shares risk factors with atherosclerosis. It has been shown that elevated LP (a) levels are associated with an increased risk for CHD across various ethnic groups. LP (a) is genetically determined, stable throughout life and yet refractory to drug therapy. While 30 mg/dl is considered the upper normal value for LP (a) in central Europe, extremely high LP (a) levels (>150mg/dl) are rare in the general population. The aim of our study was to analyse the correlation between lipoprotein (a) [LP (a)] levels and an incidence of coronary heart disease (CHD) in high-risk patients. Patients and methods We reviewed the LP (a) concentrations of 52.898 consecutive patients admitted to our cardiovascular center between January 2004 and December 2014. Of these, 579 patients had LP (a) levels above 150 mg/dl (mean 181.45±33.1mg/dl). In the control collective LP (a) was <30mg/dl (n=350). Other atherogenic risk factors in this group were HbA1c 6.58±1.65%, low density lipoprotein (LDL) 141.99±43.76 mg/dl, and body mass index 27.81±5.61. 54.40% were male, 26.07% were smokers, 93.2% had hypertension, and 24% had a family history of cardiovascular diseases. More than 82.6% were under statins. The mean glomerular filtration rate (GFR) was 69.13±24.8 ml/min [MDRD (Modification of Diet in Renal Disease)]. Results 64.98% (n=373) of the patients with LP (a) >150mg/dl had CHD. The prevalence of CHD in patients with LP (a) <30mg/dl in our control collective was 37.14%. (P- Value 0.0001). Patients with LP (a) >150mg/dl had a significantly increased risk for CHD (Odds ratio 5.98). 12.72% (n=73) of these patients suffered from CHD with single-vessel disease (VD), 14.63% (n=84) from CHD with 2VD and 37.63% (n=216) from CHD with 3VD. 47.92% of patients were re-vascularized by percutaneous coronary angioplasty (PTCA) and 37.06% of patients had to undergo coronary artery bypass grafting (CABG). 19.13% of patients had both, PTCA and CABG. Mean LP (a) level in patients with 1-vessel CHD was 181.5±29.98, in patients with 2-vessel CHD 178.94±34.26 and in patients with 3-vessel CHD 180.97±32.38 mg/dl. Conclusion Elevated LP (a) levels above 150 mg/dl are associated with a significantly increased risk of CHD in our collective and it confirms our hypothesis. Most of these patients had severe CHD with 3-vessel disease (VD) requiring coronary revascularization therapy. We need more prospective studies to confirm our findings.

Sign in / Sign up

Export Citation Format

Share Document